<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1438" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1438/" /><meta name="ncbi_pagename" content="Spinocerebellar Ataxia Type 17 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Spinocerebellar Ataxia Type 17 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Spinocerebellar Ataxia Type 17" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/09/12" /><meta name="citation_author" content="Yasuko Toyoshima" /><meta name="citation_author" content="Osamu Onodera" /><meta name="citation_author" content="Mitsunori Yamada" /><meta name="citation_author" content="Shoji Tsuji" /><meta name="citation_author" content="Hitoshi Takahashi" /><meta name="citation_pmid" content="20301611" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1438/" /><meta name="citation_keywords" content="Huntington Disease-Like 4" /><meta name="citation_keywords" content="SCA17" /><meta name="citation_keywords" content="SCA17" /><meta name="citation_keywords" content="Huntington Disease-Like 4" /><meta name="citation_keywords" content="TATA-box-binding protein" /><meta name="citation_keywords" content="TBP" /><meta name="citation_keywords" content="Spinocerebellar Ataxia Type 17" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Spinocerebellar Ataxia Type 17" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Yasuko Toyoshima" /><meta name="DC.Contributor" content="Osamu Onodera" /><meta name="DC.Contributor" content="Mitsunori Yamada" /><meta name="DC.Contributor" content="Shoji Tsuji" /><meta name="DC.Contributor" content="Hitoshi Takahashi" /><meta name="DC.Date" content="2019/09/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1438/" /><meta name="description" content="Spinocerebellar ataxia type 17 (SCA17) is characterized by ataxia, dementia, and involuntary movements, including chorea and dystonia. Psychiatric symptoms, pyramidal signs, and rigidity are common. The age of onset ranges from three to 55 years. Individuals with full-penetrance alleles develop neurologic and/or psychiatric symptoms by age 50 years. Ataxia and psychiatric abnormalities are frequently the initial findings, followed by involuntary movement, parkinsonism, dementia, and pyramidal signs. Brain MRI shows variable atrophy of the cerebrum, brain stem, and cerebellum. The clinical features correlate with the length of the polyglutamine expansion but are not absolutely predictive of the clinical course." /><meta name="og:title" content="Spinocerebellar Ataxia Type 17" /><meta name="og:type" content="book" /><meta name="og:description" content="Spinocerebellar ataxia type 17 (SCA17) is characterized by ataxia, dementia, and involuntary movements, including chorea and dystonia. Psychiatric symptoms, pyramidal signs, and rigidity are common. The age of onset ranges from three to 55 years. Individuals with full-penetrance alleles develop neurologic and/or psychiatric symptoms by age 50 years. Ataxia and psychiatric abnormalities are frequently the initial findings, followed by involuntary movement, parkinsonism, dementia, and pyramidal signs. Brain MRI shows variable atrophy of the cerebrum, brain stem, and cerebellum. The clinical features correlate with the length of the polyglutamine expansion but are not absolutely predictive of the clinical course." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1438/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/sca17/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1438/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A2655E0414E6100000000019F009F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1438_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1438_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sca15/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sca20/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1438_"><span class="title" itemprop="name">Spinocerebellar Ataxia Type 17</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Huntington Disease-Like 4, SCA17</div><p class="contrib-group"><span itemprop="author">Yasuko Toyoshima</span>, MD, PhD, <span itemprop="author">Osamu Onodera</span>, MD, PhD, <span itemprop="author">Mitsunori Yamada</span>, MD, PhD, <span itemprop="author">Shoji Tsuji</span>, MD, PhD, and <span itemprop="author">Hitoshi Takahashi</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1438_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1438_ai__"><div class="contrib half_rhythm"><span itemprop="author">Yasuko Toyoshima</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />Brain Disease Center<br />Agano Hospital<br />Agano, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ro.onaga@amihsoyot" class="oemail">pj.ro.onaga@amihsoyot</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Osamu Onodera</span>, MD, PhD<div class="affiliation small">Professor, Department of Neurology<br />Brain Research Institute<br />Niigata University<br />Niigata, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ca.u-atagiin.irb@aredono" class="oemail">pj.ca.u-atagiin.irb@aredono</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mitsunori Yamada</span>, MD, PhD<div class="affiliation small">Professor, Division of Neuropathology<br />Department of Brain Disease Research<br />Shinshu University School of Medicine<br />Matsumoto, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ca.u-uhsnihs@iron" class="oemail">pj.ca.u-uhsnihs@iron</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Shoji Tsuji</span>, MD, PhD<div class="affiliation small">Professor, Department of Neurology<br />University of Tokyo Graduate School of Medicine<br />Tokyo, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ca.oykot-u.m@ijust" class="oemail">pj.ca.oykot-u.m@ijust</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Hitoshi Takahashi</span>, MD, PhD<div class="affiliation small">Executive Vice-President for Research<br />Niigata University<br />Niigata, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ca.u-atagiin.irb@ihsotih" class="oemail">pj.ca.u-atagiin.irb@ihsotih</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 29, 2005</span>; Last Update: <span itemprop="dateModified">September 12, 2019</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="sca17.Summary" itemprop="description"><h2 id="_sca17_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Spinocerebellar ataxia type 17 (SCA17) is characterized by ataxia, dementia, and involuntary movements, including chorea and dystonia. Psychiatric symptoms, pyramidal signs, and rigidity are common. The age of onset ranges from three to 55 years. Individuals with full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles develop neurologic and/or psychiatric symptoms by age 50 years. Ataxia and psychiatric abnormalities are frequently the initial findings, followed by involuntary movement, parkinsonism, dementia, and pyramidal signs. Brain MRI shows variable atrophy of the cerebrum, brain stem, and cerebellum. The clinical features correlate with the length of the polyglutamine expansion but are not absolutely predictive of the clinical course.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of SCA17 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of an abnormal CAG/CAA repeat expansion in <i>TBP</i>. Affected individuals usually have more than 41 repeats. The CAA and CAG codons both encode glutamine residues resulting in a pathogenic polyglutamine expansion.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Psychotropic medications for psychiatric problems, antiepileptic drugs for seizures (AEDs); botulinum toxin injections for dystonia; adaptation of the environment to accommodate dementia.</p><p><i>Prevention of secondary complications:</i> Side effects of psychotropic medications and AEDs may require total or intermittent discontinuation of the treatment or reduction in dose.</p><p><i>Surveillance:</i> Annual or semiannual evaluation by a neurologist or more frequently if symptoms are progressing rapidly.</p><p><i>Agents/circumstances to avoid:</i> Sedative/hypnotic agents, such as ethanol or certain medications, may exacerbate incoordination.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SCA17 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Offspring of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are at a 50% risk of inheriting the expanded <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be precisely predicted by family history or size of expansion. Prenatal testing for pregnancies at increased risk is possible if the diagnosis has been established in an affected family member by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div></div><div id="sca17.Diagnosis"><h2 id="_sca17_Diagnosis_">Diagnosis</h2><div id="sca17.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Spinocerebellar ataxia type 17 (SCA17) <b>should be suspected</b> in individuals with the following:</p><ul><li class="half_rhythm"><div>Ataxia</div></li><li class="half_rhythm"><div>Dementia</div></li><li class="half_rhythm"><div>Involuntary movements &#x02013; e.g., chorea and dystonia (blepharospasm, torticollis, writer's cramp, foot dystonia)</div></li><li class="half_rhythm"><div>Psychiatric symptoms</div></li></ul></div><div id="sca17.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of SCA17 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of CAG (and sometimes CAA) repeats in <i>TBP</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1438/table/sca17.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figsca17Tmoleculargenetictestingusedi" rid-ob="figobsca17Tmoleculargenetictestingusedi">Table 1</a>). Because both codons CAA and CAG encode glutamine residues, the resulting proteins will have variable tracts of glutamine residues.</p><p><b>Allele sizes.</b> The structure of the repeat sequence in a normal, stably transmitted <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is variable but typically consists of series of CAG repeats interrupted by CAA repeats &#x02013; e.g., (CAG)<sub>3</sub> (CAA)<sub>3</sub> (CAG)<sub>9</sub> CAA CAG CAA (CAG)<sub>16</sub> CAA CAG. Allele size (sometimes expressed as length or number of repeats) is determined by counting all triplet repeats; the total number of CAG/CAA repeats in the example above would be 36, which would translate to 36 contiguous glutamine residues in the protein.</p><ul><li class="half_rhythm"><div><b>Normal alleles.</b> 25 to 40 CAG/CAA repeats</div></li><li class="half_rhythm"><div><b>Mutable normal alleles.</b> Not reported to date</div></li><li class="half_rhythm"><div><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles.</b> 41 to 48 CAG/CAA repeats. An individual with an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in this range may or may not develop symptoms. The significance of alleles of 41 and 44 repeats is particularly controversial because penetrance is estimated to be 50%, making <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> difficult. One symptomatic individual having 41 repeats and four symptomatic persons having 42 repeats have been reported [<a class="bk_pop" href="#sca17.REF.nanda.2007.436">Nanda et al 2007</a>, <a class="bk_pop" href="#sca17.REF.nolte.2010.1396">Nolte et al 2010</a>].</div></li><li class="half_rhythm"><div><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles.</b> 49 or greater CAG/CAA repeats. The largest repeat size reported to date is 66 [<a class="bk_pop" href="#sca17.REF.maltecca.2003.1441">Maltecca et al 2003</a>].</div></li></ul><p><b>CAA CAG CAA interruption.</b> The CAA CAG CAA interruption between (CAG)<sub>x</sub> and (CAG)<sub>y</sub> is present in all expanded alleles that are stably transmitted (i.e., the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> size is unchanged during meiosis).</p><p>The CAA CAG CAA interruption between (CAG)<sub>x</sub> and (CAG)<sub>y</sub> was absent in two families with <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> size instability (i.e., change in allele size) during transmission [<a class="bk_pop" href="#sca17.REF.z_hlke.2001.160">Z&#x000fc;hlke et al 2001</a>, <a class="bk_pop" href="#sca17.REF.maltecca.2003.1441">Maltecca et al 2003</a>]. Thus, loss of this interruption may be a prerequisite of instability in SCA17 as in other disorders caused by repeat expansions [<a class="bk_pop" href="#sca17.REF.maltecca.2003.1441">Maltecca et al 2003</a>, <a class="bk_pop" href="#sca17.REF.z_hlke.2003b.629">Z&#x000fc;hlke et al 2003b</a>, <a class="bk_pop" href="#sca17.REF.z_hlke.2005.27">Z&#x000fc;hlke et al 2005</a>].</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Targeted analysis for a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> CAG/CAA repeat number in <i>TBP</i> should be performed first.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TBP</i> CAG/CAA repeat analysis and other genes of interest (see <a href="#sca17.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="sca17.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Spinocerebellar Ataxia Type 17</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1438/table/sca17.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca17.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca17.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_sca17.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_sca17.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_sca17.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TBP</i></td><td headers="hd_h_sca17.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for CAG/CAA repeat expansion&#x000a0;<sup>3</sup></td><td headers="hd_h_sca17.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="sca17.TF.1.1"><p class="no_margin">See <a href="/books/NBK1438/#sca17.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="sca17.TF.1.2"><p class="no_margin">See <a href="#sca17.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="sca17.TF.1.3"><p class="no_margin"><a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> amplification will likely detect CAG/CAA repeat expansions of 66 or fewer.</p></div></dd></dl></div></div></div></div></div><div id="sca17.Clinical_Characteristics"><h2 id="_sca17_Clinical_Characteristics_">Clinical Characteristics</h2><div id="sca17.Clinical_Description"><h3>Clinical Description</h3><p>Spinocerebellar ataxia type 17 (SCA17) is characterized by ataxia (95%), dementia (~90%), and involuntary movements (~70%), including chorea and dystonia (blepharospasm, torticollis, writer's cramp, foot dystonia) [<a class="bk_pop" href="#sca17.REF.cellini.2004.163">Cellini et al 2004</a>, <a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>]. Psychiatric symptoms, pyramidal signs, and rigidity are common.</p><p>Onset ranges from age three to 75 years (mean: 34.6 years) [<a class="bk_pop" href="#sca17.REF.stevanin.2008.170">Stevanin &#x00026; Brice 2008</a>]. All individuals with full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles develop neurologic and/or psychiatric symptoms by age 50 years [<a class="bk_pop" href="#sca17.REF.koide.1999.2047">Koide et al 1999</a>; <a class="bk_pop" href="#sca17.REF.fujigasaki.2001.1939">Fujigasaki et al 2001</a>; <a class="bk_pop" href="#sca17.REF.nakamura.2001.1441">Nakamura et al 2001</a>; <a class="bk_pop" href="#sca17.REF.z_hlke.2001.160">Z&#x000fc;hlke et al 2001</a>; <a class="bk_pop" href="#sca17.REF.silveira.2002.623">Silveira et al 2002</a>; <a class="bk_pop" href="#sca17.REF.maltecca.2003.1441">Maltecca et al 2003</a>; <a class="bk_pop" href="#sca17.REF.stevanin.2003.1599">Stevanin et al 2003</a>; <a class="bk_pop" href="#sca17.REF.z_hlke.2003b.629">Z&#x000fc;hlke et al 2003b</a>; <a class="bk_pop" href="#sca17.REF.bauer.2004.230">Bauer et al 2004</a>; <a class="bk_pop" href="#sca17.REF.hagenah.2004.217">Hagenah et al 2004</a>; <a class="bk_pop" href="#sca17.REF.oda.2004.209">Oda et al 2004</a>; <a class="bk_pop" href="#sca17.REF.toyoshima.2018.219">Toyoshima &#x00026; Takahashi 2018</a>; Toyoshima, personal observation].</p><p>Although the disease course is variable, ataxia and psychiatric abnormalities are frequently the initial findings, followed by involuntary movement, parkinsonism, dementia, and pyramidal signs.</p><p><b>Brain MRI</b> shows variable atrophy of the cerebrum, brain stem, and cerebellum (<a class="figpopup" href="/books/NBK1438/figure/sca17.F1/?report=objectonly" target="object" rid-figpopup="figsca17F1" rid-ob="figobsca17F1">Figure 1</a>). Most people present with cerebellar atrophy. The age of the individual and the length of CAG/CAA repeat influence the degree of atrophy. For example, in older individuals &#x02013; even those with a small <a class="def" href="/books/n/gene/glossary/def-item/full-penetrance-allele/">full-penetrance allele</a> &#x02013; severe atrophy is present on brain MRI. High-intensity T<sub>2</sub>-weighted images and selective atrophy on caudate nucleus are not observed. Some correlation of region of brain atrophy with clinical characteristics is seen [<a class="bk_pop" href="#sca17.REF.lasek.2006.2341">Lasek et al 2006</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figsca17F1" co-legend-rid="figlgndsca17F1"><a href="/books/NBK1438/figure/sca17.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figsca17F1" rid-ob="figobsca17F1"><img class="small-thumb" src="/books/NBK1438/bin/sca17-Image001.gif" src-large="/books/NBK1438/bin/sca17-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndsca17F1"><h4 id="sca17.F1"><a href="/books/NBK1438/figure/sca17.F1/?report=objectonly" target="object" rid-ob="figobsca17F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Number of CAG/CAA repeats versus age of individuals with SCA17 </p></div></div><p><b>Neuropathology.</b> The brain shows atrophy of the striatum (more apparent in the caudate nucleus) and cerebellum. Histologically, neuronal loss is observed in the striatum and Purkinje cell layer. Loss of cerebral cortical neurons is seen in some individuals.</p><p>Immunohistochemistry for the expanded polyglutamine (polyQ) tracts shows diffuse labeling of the neuronal nucleoplasm.</p><p>Note: Intranuclear inclusions are a much less common finding than diffuse labeling. No labeling is detectable in the cytoplasm or in the neuropil. Glial cell involvement is occasionally seen.</p><p>In individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for an expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> range, nuclear polyQ pathology involves other CNS regions including the cerebral cortex, thalamus, and brain stem [<a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>]. The abundant nuclear accumulation of polyQ in the cerebral cortices and subcortical nuclei (e.g., dorsomedian thalamic nucleus) are possibly associated with the prominent cognitive and behavioral decline in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="sca17.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><div id="sca17.Heterozygotes"><h4>Heterozygotes</h4><p><b>Clinical features.</b> The length of the CAG/CAA repeat in <i>TBP</i> correlates with the clinical features based on data available from 52 individuals (50 from the literature and 2 unreported) (<a class="figpopup" href="/books/NBK1438/table/sca17.T.frequency_of_clinical_features_i/?report=objectonly" target="object" rid-figpopup="figsca17Tfrequencyofclinicalfeaturesi" rid-ob="figobsca17Tfrequencyofclinicalfeaturesi">Table 2</a>, <a class="figpopup" href="/books/NBK1438/figure/sca17.F2/?report=objectonly" target="object" rid-figpopup="figsca17F2" rid-ob="figobsca17F2">Figure 2</a>). As the information reported in the literature was incomplete, the frequencies listed for symptom occurrence may be underestimated [<a class="bk_pop" href="#sca17.REF.koide.1999.2047">Koide et al 1999</a>, <a class="bk_pop" href="#sca17.REF.fujigasaki.2001.1939">Fujigasaki et al 2001</a>, <a class="bk_pop" href="#sca17.REF.nakamura.2001.1441">Nakamura et al 2001</a>, <a class="bk_pop" href="#sca17.REF.z_hlke.2001.160">Z&#x000fc;hlke et al 2001</a>, <a class="bk_pop" href="#sca17.REF.silveira.2002.623">Silveira et al 2002</a>, <a class="bk_pop" href="#sca17.REF.maltecca.2003.1441">Maltecca et al 2003</a>, <a class="bk_pop" href="#sca17.REF.rolfs.2003.367">Rolfs et al 2003</a>, <a class="bk_pop" href="#sca17.REF.stevanin.2003.1599">Stevanin et al 2003</a>, <a class="bk_pop" href="#sca17.REF.z_hlke.2003a.161">Z&#x000fc;hlke et al 2003a</a>, <a class="bk_pop" href="#sca17.REF.bauer.2004.230">Bauer et al 2004</a>, <a class="bk_pop" href="#sca17.REF.hagenah.2004.217">Hagenah et al 2004</a>, <a class="bk_pop" href="#sca17.REF.oda.2004.209">Oda et al 2004</a>]. Of note is the high proportion of individuals with psychiatric symptoms and chorea.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figsca17F2" co-legend-rid="figlgndsca17F2"><a href="/books/NBK1438/figure/sca17.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figsca17F2" rid-ob="figobsca17F2"><img class="small-thumb" src="/books/NBK1438/bin/sca17-Image002.gif" src-large="/books/NBK1438/bin/sca17-Image002.jpg" alt="Figure 2. . The clinical features in SCA17 depend on the length of CAG/CAA repeats." /></a><div class="icnblk_cntnt" id="figlgndsca17F2"><h4 id="sca17.F2"><a href="/books/NBK1438/figure/sca17.F2/?report=objectonly" target="object" rid-ob="figobsca17F2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">The clinical features in SCA17 depend on the length of CAG/CAA repeats. The clinical features reported in affected individuals are denoted by letter. For example, A-E denotes affected individuals who have ataxia with parkinsonism. A = ataxia</p></div></div><ul><li class="half_rhythm"><div><b>CAG/CAA repeat size from 41 to 50.</b> More than 75% of individuals have intellectual deterioration; in some individuals, intellectual problems and involuntary movements are the only signs. Psychiatric symptoms or dementia, parkinsonism, and chorea &#x02013; a clinical constellation resembling Huntington disease &#x02013; are more frequently observed in individuals with CAG/CAA repeats in this range than in individuals with larger repeats [<a class="bk_pop" href="#sca17.REF.stevanin.2003.1599">Stevanin et al 2003</a>, <a class="bk_pop" href="#sca17.REF.bauer.2004.230">Bauer et al 2004</a>, <a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>].</div></li><li class="half_rhythm"><div><b>CAG/CAA repeat size from 43 to 47.</b> Individuals with an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of 43-47 repeats tend to have a parkinsonian <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#sca17.REF.kim.2009.1385">Kim et al 2009</a>, <a class="bk_pop" href="#sca17.REF.chen.2010.375">Chen et al 2010</a>].</div></li><li class="half_rhythm"><div><b>CAG/CAA repeat size from 50 to 60.</b> All individuals have ataxia and 75% have reduced intellectual function. Pyramidal signs (e.g., increased deep tendon reflexes) and dystonia are more common than in those with smaller repeats.</div></li><li class="half_rhythm"><div><b>CAG/CAA repeat size greater than 60.</b> Two individuals with repeats in this size range have been reported. The largest CAG/CAA repeat is 66 repeats, observed in one <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> case [<a class="bk_pop" href="#sca17.REF.maltecca.2003.1441">Maltecca et al 2003</a>]. The child developed gait disturbance at age three years followed by spasticity, dementia, and psychiatric symptoms. The other child, who had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> CAG repeat expansion of 63 repeats, developed ataxia and intellectual deterioration at age six years followed later by spasticity [<a class="bk_pop" href="#sca17.REF.koide.1999.2047">Koide et al 1999</a>]. Brain MRI showed severe atrophy in the cerebrum, cerebellum, and brain stem.</div></li></ul><div id="sca17.T.frequency_of_clinical_features_i" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Frequency of Clinical Features in Spinocerebellar Ataxia Type 17 Correlated with <i>TBP</i> Repeat Size</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1438/table/sca17.T.frequency_of_clinical_features_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca17.T.frequency_of_clinical_features_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CAG/CAA<br />Repeat Size<br />of Allele</th><th id="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia</th><th id="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dementia /<br />Psychiatric<br />Symptoms</th><th id="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Increased<br />DTRs</th><th id="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia</th><th id="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parkinsonism</th><th id="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea</th></tr></thead><tbody><tr><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41-49</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35%</td></tr><tr><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02265;50</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">88%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">56%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">56%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">48%</td><td headers="hd_h_sca17.T.frequency_of_clinical_features_i_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#sca17.REF.toyoshima.2018.219">Toyoshima &#x00026; Takahashi [2018]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">DTRs = deep tendon reflexes</p></div></dd></dl></div></div></div></div><div id="sca17.Homozygotes"><h4>Homozygotes</h4><p>Four <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> individuals and one <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> individual have been reported [<a class="bk_pop" href="#sca17.REF.z_hlke.2003b.629">Z&#x000fc;hlke et al 2003b</a>, <a class="bk_pop" href="#sca17.REF.oda.2004.209">Oda et al 2004</a>, <a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>, <a class="bk_pop" href="#sca17.REF.hire.2011.472">Hire et al 2011</a>]. Four individuals who were homozygous for 47 or 48 CAG/CAA repeats had onset in the fourth decade, not unlike the age of onset predicted for heterozygotes [<a class="bk_pop" href="#sca17.REF.z_hlke.2003b.629">Z&#x000fc;hlke et al 2003b</a>, <a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>]. Their symptoms were severe and rapidly progressive, and in one individual differed from those of his parents, suggesting that the presence of two expanded alleles influences the severity and rate of progression of symptoms.</p></div></div><div id="sca17.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of alleles of 41-44 repeats is estimated at 50% and the penetrance of alleles of 45-48 repeats is estimated at greater than 80% [<a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>].</p><ul><li class="half_rhythm"><div>Individuals with 41 CAA/CAG repeats developed ataxia and mild dementia [<a class="bk_pop" href="#sca17.REF.nanda.2007.436">Nanda et al 2007</a>, <a class="bk_pop" href="#sca17.REF.doherty.2014.36">Doherty et al 2014</a>]. Two individuals who had 41 repeats developed parkinsonism and chorea [<a class="bk_pop" href="#sca17.REF.herrema.2014.269">Herrema et al 2014</a>, <a class="bk_pop" href="#sca17.REF.park.2016.106">Park et al 2016</a>]. One individual with 41 repeats developed late-onset chorea and psychiatric symptoms [<a class="bk_pop" href="#sca17.REF.alibardi.2014.678">Alibardi et al 2014</a>].</div></li><li class="half_rhythm"><div>Four individuals with 42 CAG/CAA repeats developed a relatively benign <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> consisting of mild gait ataxia, dysarthria, and dysdiadochokinesia [<a class="bk_pop" href="#sca17.REF.nolte.2010.1396">Nolte et al 2010</a>].</div></li><li class="half_rhythm"><div>An individual with 43 CAG/CAA repeats developed ataxia with dementia at age 52 years [<a class="bk_pop" href="#sca17.REF.silveira.2002.623">Silveira et al 2002</a>]; six individuals diagnosed with parkinsonism were found to have 43 CAG/CAA repeats [<a class="bk_pop" href="#sca17.REF.kim.2009.1385">Kim et al 2009</a>]. An individual with 43 repeats developed severe dementia [<a class="bk_pop" href="#sca17.REF.nielsen.2012.73">Nielsen et al 2012</a>].</div></li><li class="half_rhythm"><div>An individual with 46 CAG/CAA repeats developed symptoms at age 75 years, the latest onset observed to date [<a class="bk_pop" href="#sca17.REF.wu.2005.539">Wu et al 2005</a>].</div></li><li class="half_rhythm"><div>Asymptomatic elderly individuals with 43-49 CAG/CAA repeats have also been reported [<a class="bk_pop" href="#sca17.REF.nakamura.2001.1441">Nakamura et al 2001</a>, <a class="bk_pop" href="#sca17.REF.z_hlke.2003a.161">Z&#x000fc;hlke et al 2003a</a>, <a class="bk_pop" href="#sca17.REF.oda.2004.209">Oda et al 2004</a>, <a class="bk_pop" href="#sca17.REF.z_hlke.2005.27">Z&#x000fc;hlke et al 2005</a>, <a class="bk_pop" href="#sca17.REF.mariotti.2007.1538">Mariotti et al 2007</a>].</div></li></ul><p><b>Age of onset.</b> The correlation between the size of the CAG/CAA repeat and the age of onset in SCA17 (<a class="figpopup" href="/books/NBK1438/figure/sca17.F3/?report=objectonly" target="object" rid-figpopup="figsca17F3" rid-ob="figobsca17F3">Figure 3</a>) is not as strong as in other disorders (<a href="/books/n/gene/sca1/">SCA1</a>, <a href="/books/n/gene/sca2/">SCA2</a>, <a href="/books/n/gene/sca3/">SCA3</a>, <a href="/books/n/gene/sca6/">SCA6</a>, <a href="/books/n/gene/sca7/">SCA7</a>, <a href="/books/n/gene/huntington/">Huntington disease</a>, <a href="/books/n/gene/drpla/">DRPLA</a>, <a href="/books/n/gene/kennedy/">SBMA</a>]) caused by expansion of a polyglutamine tract [<a class="bk_pop" href="#sca17.REF.rolfs.2003.367">Rolfs et al 2003</a>, <a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>,<a class="bk_pop" href="#sca17.REF.toyoshima.2018.219">Toyoshima &#x00026; Takahashi 2018</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figsca17F3" co-legend-rid="figlgndsca17F3"><a href="/books/NBK1438/figure/sca17.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figsca17F3" rid-ob="figobsca17F3"><img class="small-thumb" src="/books/NBK1438/bin/sca17-Image003.gif" src-large="/books/NBK1438/bin/sca17-Image003.jpg" alt="Figure 3. " /></a><div class="icnblk_cntnt" id="figlgndsca17F3"><h4 id="sca17.F3"><a href="/books/NBK1438/figure/sca17.F3/?report=objectonly" target="object" rid-ob="figobsca17F3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Correlation between age at onset and length of CAG/CAA repeat in individuals with SCA17 For references, see Penetrance, <i>Age of onset</i>.</p></div></div></div><div id="sca17.Nomenclature"><h3>Nomenclature</h3><p><a class="bk_pop" href="#sca17.REF.bauer.2004.230">Bauer et al [2004]</a> reported nine individuals with <i>TBP</i> alleles larger than 45 CAG/CAA repeats among 1,712 individuals with Huntington disease-like 2, and observed that CAG/CAA repeat expansions in <i>TBP</i> represented a more common monogenic cause for a Huntington disease-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> than Huntington disease-like 1 [<a class="bk_pop" href="#sca17.REF.xiang.1998.1431">Xiang et al 1998</a>] or Huntington disease-like 2 [<a class="bk_pop" href="#sca17.REF.margolis.2001.373">Margolis et al 2001</a>]. Therefore, SCA17 is also referred to as Huntington disease-like 4 [<a class="bk_pop" href="#sca17.REF.stevanin.2003.1599">Stevanin et al 2003</a>, <a class="bk_pop" href="#sca17.REF.schneider.2007.517">Schneider et al 2007</a>, <a class="bk_pop" href="#sca17.REF.harbo.2009.777">Harbo et al 2009</a>].</p></div><div id="sca17.Anticipation"><h3>Anticipation</h3><p>Instability of the <i>TBP</i> CAG repeat in <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> transmission is not clear in SCA17 [<a class="bk_pop" href="#sca17.REF.fujigasaki.2001.1939">Fujigasaki et al 2001</a>, <a class="bk_pop" href="#sca17.REF.nakamura.2001.1441">Nakamura et al 2001</a>, <a class="bk_pop" href="#sca17.REF.shatunov.2004.496">Shatunov et al 2004</a>]. CAG repeats in <i>TBP</i> have two distinct configurations, which are differentiated by the absence or presence of CAA <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> interruptions. The basic structure of the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is (CAG)<sub>3</sub> (CAA)<sub>3</sub> (CAG)<sub>x</sub> CAA CAG CAA (CAG)<sub>y</sub> CAA CAG. If the basic structure is broken (i.e., CAA repeat interruptions are absent), repeat stability may be reduced. In German and Italian families, an absence of CAA interruptions resulting in longer pure tracts of CAG repeats was detected. It is of note that intergenerational instability and <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> were documented in these families [<a class="bk_pop" href="#sca17.REF.z_hlke.2001.160">Z&#x000fc;hlke et al 2001</a>, <a class="bk_pop" href="#sca17.REF.maltecca.2003.1441">Maltecca et al 2003</a>]. It has been proposed that CAA interruptions may serve as a limiting element for further expansion of CAG repeats in <i>TBP</i> [<a class="bk_pop" href="#sca17.REF.gao.2008.215">Gao et al 2008</a>].</p><p>The phenomenon termed <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a>, a trend toward an earlier age at onset and more severe disease manifestations in offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, is infrequently documented in families with SCA17. In addition, because of low <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the intermediate alleles (41-48 repeats), the age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be predicted by family history or size of expansion.</p></div><div id="sca17.Prevalence"><h3>Prevalence</h3><p>Fewer than 100 families with SCA17 have been reported.</p><p>The prevalence of SCA17 in the Japanese population is estimated at 0.47:1,000,000. SCA17 accounts for approximately 0.3% of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> SCA [<a class="bk_pop" href="#sca17.REF.maruyama.2002.578">Maruyama et al 2002</a>].</p><p>The minimum prevalence of SCA17 in northeast England is 0.16:100,000 [<a class="bk_pop" href="#sca17.REF.craig.2005.105">Craig et al 2005</a>].</p><p>In a study of the Yugoslav population, none of the 115 individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> cerebellar ataxia or <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases of adult-onset ataxia had SCA17 [<a class="bk_pop" href="#sca17.REF.alendar.2004.185">Alendar et al 2004</a>].</p><p>The prevalence of SCA17 may be underestimated because some individuals with SCA17 have a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> similar to that of <a href="/books/n/gene/huntington/">Huntington disease</a>.</p></div></div><div id="sca17.Genetically_Related_Allelic_Disord"><h2 id="_sca17_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No other phenotypes are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>TBP</i>.</p></div><div id="sca17.Differential_Diagnosis"><h2 id="_sca17_Differential_Diagnosis_">Differential Diagnosis</h2><div id="sca17.T.inherited_conditions_to_consider" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Inherited Conditions to Consider in the Differential Diagnosis of Spinocerebellar Ataxia Type 17 (SCA17)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1438/table/sca17.T.inherited_conditions_to_consider/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca17.T.inherited_conditions_to_consider_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential<br />Diagnosis<br />Disorder</th><th id="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of the Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4" id="hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/SCA17</th><th headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4" id="hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from SCA17</th></tr></thead><tbody><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary cerebellar ataxia (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>)</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR<br />XL</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar ataxia</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary cerebellar ataxia associated w/prominent cerebellar &#x00026; long tract signs</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/drpla/">DRPLA</a> (dentatorubral-pallidoluysian atrophy)</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATN1</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive ataxia &#x00026; dementia; psychiatric disturbances</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia &#x00026; myoclonus are prominent movement disorders.</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/huntington/">Huntington disease</a> (HD)</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HTT</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive movement disorders &#x00026; dementia; psychiatric disturbances</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive chorea is prominent.</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/als-ftd/"><i>C9orf72</i>-related amyotrophic lateral sclerosis and frontotemporal dementia</a></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>C9orf72</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Movement disorders, dementia, psychiatric disturbances</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myoclonus, tremor, torticollis</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Huntington disease-like 1 (OMIM <a href="http://www.omim.org/entry/603218" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603218</a>)&#x000a0;<sup>1</sup></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRNP</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range of clinical features that overlap w/HD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early onset, slowly progressive</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hd-l2/">Huntington disease-like 2</a></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>JPH3</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinically indistinguishable from HD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prevalence highest in (&#x00026; perhaps exclusive to) individuals of African descent</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/chac/">Chorea-acanthocytosis</a></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VPS13A</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive movement disorder &#x00026; cognitive &#x00026; behavior changes</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myopathy, &#x02191; serum CK, acanthocytosis; seizures common; mean onset age ~30 yrs</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mcleod/">McLeod neuroacanthocytosis syndrome</a></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XK</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cognitive impairment, psychiatric symptoms</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acanthocytosis, compensated hemolysis, McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benign hereditary chorea (OMIM <a href="http://www.omim.org/entry/118700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">118700</a>)</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NKX2-1</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea is non-progressive &#x00026; not associated w/dementia.</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial Creutzfeld-Jakob disease (fCJD; see <a href="/books/n/gene/prion/">Genetic Prion Diseases</a>)</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRNP</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically late onset; progressive dementia; movement disorders, behavior changes, &#x00026; psychiatric symptoms</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">fCJD progresses more rapidly; myoclonus is a prominent involuntary movement.</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/alzheimer-early/">Early-onset familial Alzheimer disease</a></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>APP</i><br /><i>PSEN1</i><br /><i>PSEN2</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dementia</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No movement disorders</td></tr><tr><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial frontotemporal dementia w/parkinsonism-17 (FTDP-17; see <a href="/books/n/gene/ftdp-17/"><i>MAPT</i>-Related Disorders</a>)</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAPT</i></td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Late onset; progressive movement disorders, dementia, behavior changes; psychiatric disturbances</td><td headers="hd_h_sca17.T.inherited_conditions_to_consider_1_1_1_4 hd_h_sca17.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No chorea</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; CK = creatine kinase; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="sca17.TF.3.1"><p class="no_margin">Huntington disease-like 1 is caused by a specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (8 extra octapeptide repeats) in the prion protein <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, <i>PRNP</i>, on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 20p [<a class="bk_pop" href="#sca17.REF.laplanche.1999.2375">Laplanche et al 1999</a>, <a class="bk_pop" href="#sca17.REF.moore.2001.1385">Moore et al 2001</a>]. Similar pathogenic variants at this <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> also result in other forms of prion disease, such as <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> Creutzfeldt-Jakob disease (see <a href="/books/n/gene/prion/">Genetic Prion Diseases</a>).</p></div></dd></dl></div></div></div></div><div id="sca17.Management"><h2 id="_sca17_Management_">Management</h2><div id="sca17.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 17 (SCA17), the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Neuropsychological testing to evaluate for dementia and/or psychiatric disturbance</div></li><li class="half_rhythm"><div>Brain MRI to evaluate areas and degree of atrophy</div></li><li class="half_rhythm"><div>Neurology consultation, if not completed prior to initial diagnosis</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="sca17.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="sca17.T.treatment_of_manifestations_in_i" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Spinocerebellar Ataxia Type 17</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1438/table/sca17.T.treatment_of_manifestations_in_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca17.T.treatment_of_manifestations_in_i_lrgtbl__"><table><thead><tr><th id="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/Concern</th><th id="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th></tr></thead><tbody><tr><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Psychiatric symptoms</td><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Psychotropic medications</td></tr><tr><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Antiepileptic drugs (AEDs)</td></tr><tr><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia</td><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Local injections of botulinum toxin</td></tr><tr><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dementia</td><td headers="hd_h_sca17.T.treatment_of_manifestations_in_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adaptation of environment</td></tr></tbody></table></div></div></div><div id="sca17.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p>The side effects of psychotropic medications and AEDs (e.g., depression, sedation, nausea, restlessness, headache, neutropenia, and tardive dyskinesia) can be major secondary complications in persons with SCA17. For some individuals, the side effects of certain therapeutics may be worse than the symptoms of the disease; such individuals may benefit from total or intermittent discontinuation of the treatment or reduction in dose.</p></div><div id="sca17.Surveillance"><h3>Surveillance</h3><p>Affected individuals should be followed annually or semiannually by a neurologist or more frequently if symptoms are progressing rapidly, as may happen in the advanced stages [<a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>].</p></div><div id="sca17.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Agents with sedative/hypnotic properties, such as ethanol or certain medications, may markedly increase incoordination.</p></div><div id="sca17.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#sca17.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="sca17.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="sca17.Genetic_Counseling"><h2 id="_sca17_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="sca17.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Spinocerebellar ataxia type 17 (SCA17) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="sca17.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x000a0;*</b></p><ul><li class="half_rhythm"><div>Approximately 50% of individuals diagnosed with SCA17 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with SCA17 may have the disorder as a result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> expansion in <i>TBP</i>. Although 38% of individuals with SCA17 represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., only one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> person in the family), most of these families have not been evaluated sufficiently to determine if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> occurred <i>de novo</i>; therefore, the proportion of cases caused by a <i>de novo</i> expansion is unknown [<a class="bk_pop" href="#sca17.REF.koide.1999.2047">Koide et al 1999</a>, <a class="bk_pop" href="#sca17.REF.shatunov.2004.496">Shatunov et al 2004</a>, <a class="bk_pop" href="#sca17.REF.bech.2010.12">Bech et al 2010</a>].</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> expansion.</div></li><li class="half_rhythm"><div>If an expansion (&#x0003e;40 CAG/CAA repeats) of <i>TBP</i> cannot be detected in the DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> expansion in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> or, theoretically, <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent, or expansion from a mutable normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the parent.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with SCA17 may appear to be negative because of failure to recognize the disorder in family members due to its extremely variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, early death of the parent before the onset of symptoms, late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p>*&#x000a0;Based on the family history of the 59 reported families with <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#sca17.REF.toyoshima.2018.219">Toyoshima &#x00026; Takahashi 2018</a>]</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If one of the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an expanded <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, the risk to the sibs of inheriting the expanded CAG/CAA allele is 50%. The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be precisely predicted by family history or size of expansion.</div></li><li class="half_rhythm"><div>If an expansion (&#x0003e;40 CAG/CAA repeats) of <i>TBP</i> cannot be detected in the DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#sca17.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>If the parents have not been tested for the expanded <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> but are clinically unaffected, sibs are still presumed to be at increased risk for SCA17 because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibilities of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> or expansion from a mutable normal allele in the parent.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with SCA17 has a 50% chance of inheriting the expanded <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be precisely predicted by family history or size of expansion.</div></li><li class="half_rhythm"><div>Compared with other SCA subtypes caused by expanded trinucleotide repeats, <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> is rare in SCA17 because CAA interruptions within the <i>TBP</i> CAG repeat configuration stabilize the repeat in <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> transmission (see <a href="#sca17.Anticipation">Anticipation</a>). However, if the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and a short number of repeats (41-43), examination of the CAG repeat configuration to determine if CAA repeat interruptions are present can be useful in assessing the likelihood of severe anticipation in offspring.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to have an expanded <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, his or her family members are at risk.</p></div><div id="sca17.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>Predictive testing (i.e., testing of asymptomatic at-risk individuals)</b></p><ul><li class="half_rhythm"><div>Predictive testing for at-risk relatives is possible once the molecular diagnosis of SCA17 has been confirmed in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Such testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals.</div></li><li class="half_rhythm"><div>Potential consequences of such testing (including, but not limited to, socioeconomic changes and the need for long-term follow up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> prior to testing.</div></li></ul><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals younger than age 18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p>In a family with an established diagnosis of SCA17, it is appropriate to consider testing of symptomatic individuals regardless of age.</p></div><div id="sca17.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once a diagnosis of SCA17 has been established by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for SCA17 are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="sca17.Resources"><h2 id="_sca17_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22234/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinocerebellar ataxia</a></div></li><li class="half_rhythm"><div><b>Spinocerebellar Ataxia: Making an Informed Choice about Genetic Testing</b></div><div><i>Booklet providing information about Spinocerebellar Ataxia</i></div><div><a href="http://depts.washington.edu/neurolog/images/neurogenetics/ataxia.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">depts.washington.edu/neurolog/images/neurogenetics/ataxia.pdf</a></div></li><li class="half_rhythm"><div><b>Ataxia UK</b></div><div>Lincoln House</div><div>1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> 0845 644 0606 (helpline); 020 7582 1444 (office); +44 (0) 20 7582 1444 (from abroad)</div><div><b>Email:</b> helpline@ataxia.org.uk; office@ataxia.org.uk</div><div><a href="http://www.ataxia.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org.uk</a></div></li><li class="half_rhythm"><div><b>euro-ATAXIA (European Federation of Hereditary Ataxias)</b></div><div>Ataxia UK</div><div>Lincoln House, Kennington Park, 1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 207 582 1444</div><div><b>Email:</b> smillman@ataxia.org.uk</div><div><a href="https://www.euroataxia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.euroataxia.org</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>Spanish Ataxia Federation (FEDAES)</b></div><div>Spain</div><div><b>Phone:</b> 34 983 278 029; 34 985 097 152; 34 634 597 503</div><div><b>Email:</b> sede.valladolid@fedaes.org; sede.gijon@fedaes.org; sede.bilbao@fedaes.org</div><div><a href="http://www.fedaes.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fedaes.org</a></div></li><li class="half_rhythm"><div><b>CoRDS Registry</b></div><div>Sanford Research</div><div>2301 East 60th Street North</div><div>Sioux Falls SD 57104</div><div><b>Phone:</b> 605-312-6423</div><div><b>Email:</b> sanfordresearch@sanfordhealth.org</div><div><a href="http://www.sanfordresearch.org/SpecialPrograms/cords/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CoRDS Registry</a></div></li></ul></div><div id="sca17.Molecular_Genetics"><h2 id="_sca17_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="sca17.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Spinocerebellar Ataxia Type 17: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1438/table/sca17.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca17.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_sca17.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_sca17.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_sca17.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_sca17.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_sca17.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_sca17.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_sca17.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6908" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TBP</i></a></td><td headers="hd_b_sca17.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6908" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6q27</a></td><td headers="hd_b_sca17.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P20226" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TATA-box-binding protein</a></td><td headers="hd_b_sca17.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/TBP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TBP database</a></td><td headers="hd_b_sca17.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TBP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TBP</a></td><td headers="hd_b_sca17.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TBP[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TBP</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="sca17.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="sca17.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Spinocerebellar Ataxia Type 17 (<a href="/omim/600075,607136" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1438/table/sca17.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sca17.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600075" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600075</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TATA BOX-BINDING PROTEIN; TBP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607136" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607136</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINOCEREBELLAR ATAXIA 17; SCA17</td></tr></tbody></table></div></div><div id="sca17.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>TATA-box-binding protein (TBP) is an important general transcription initiation factor and is the DNA-binding subunit of RNA polymerase II <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> D, the multi-subunit complex crucial for the expression of most genes. TBP has a long tract of glutamines in the N-terminus. This region is thought to modulate the DNA binding activity of the C terminus, which affects the rate of transcription complex formation and initiation of transcription.</p><p><b>Mechanism of disease causation</b></p><ul><li class="half_rhythm"><div>Unknown, but the contiguous tract of polygutamine encoded by the pathogenic expanded <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is generally considered to confer a gain of function.</div></li><li class="half_rhythm"><div>Because TBP is a fundamental <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> expressed ubiquitously in all organs, including the CNS, the question of whether loss of TBP function plays a role in the pathogenesis of spinocerebellar ataxia Type 17 (SCA17) remains to be addressed. In a homozygote, however, no abnormality was observed in growth, and pathologic examination showed no specific changes in the visceral organs [<a class="bk_pop" href="#sca17.REF.toyoshima.2004.281">Toyoshima et al 2004</a>]. Taking into consideration the ubiquitous presence of TBP, the selective neuronal degeneration suggests no significant loss of protein function in individuals with SCA17.</div></li></ul><p><b><i>TBP</i>-specific laboratory considerations</b></p><ul><li class="half_rhythm"><div>The trinucleotide CAG repeats, sometimes interrupted by CAA repeats, are in <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3. Both CAG and CAA trinucleotide repeats encode the amino acid glutamine resulting in a contiguous tract of polyglutamine at the protein level.</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> laboratory most commonly reports the number (length) of trinucleotide repeats for each <i>TBP</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>; that number is the total of both CAG and CAA repeats of a <i>TBP</i> allele. The alleles may be annotated using the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen.hgvs.org</a>) for alleles with trinucleotide sequences (<a href="http://www.hgvs.org/mutnomen/recs-DNA.html#var" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hgvs.org/mutnomen/recs-DNA.html#var</a>; see <b>Repeated sequences</b>).</div></li></ul></div></div><div id="sca17.References"><h2 id="_sca17_References_">References</h2><div id="sca17.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sca17.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 9-9-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 9-9-19.</div></li></ul></div><div id="sca17.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.alendar.2004.185">Alendar A, Euljkovic B, Savic D, Djarmati A, Keckarevic M, Ristic A, Dragasevic N, Kosic V, Romac S. Spinocerebellar ataxia type 17 in the Yugoslav population. <span><span class="ref-journal">Acta Neurol Scand. </span>2004;<span class="ref-vol">109</span>:185–7.</span> [<a href="/pubmed/14763955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14763955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.alibardi.2014.678">Alibardi A, Squitieri F, Fattapposta F, Missori P, Pierelli F, Trompetto C, Curra A. Psychiatric onset and late chorea in a patient with 41 CAG repeats in the TATA-binding protein gene. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2014;<span class="ref-vol">20</span>:678–9.</span> [<a href="/pubmed/24698056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24698056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.bauer.2004.230">Bauer P, Laccone F, Rolfs A, Wullner U, Bosch S, Peters H, Liebscher S, Scheible M, Epplen JT, Weber BH, Holinski-Feder E, Weirich-Schwaiger H, Morris-Rosendahl DJ, Andrich J, Riess O. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:230–2.</span> [<a href="/pmc/articles/PMC1735701/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735701</span></a>] [<a href="/pubmed/14985389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14985389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.bech.2010.12">Bech S, Petersen T, Norremolle A, Gjedde A, Ehlers L, Eiberg H, Hjermind LE, Hasholt L, Lundorf E, Nielsen JE. Huntington&#x02019;s disease-like and ataxia syndromes: identification of a family with a de novo SCA17/TBP mutation. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2010;<span class="ref-vol">16</span>:12–5.</span> [<a href="/pubmed/19595623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19595623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.cellini.2004.163">Cellini E, Forleo P, Nacmias B, Tedde A, Bagnoli S, Piacentini S, Sorbi S. Spinocerebellar ataxia type 17 repeat in patients with Huntington's disease-like and ataxia. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">56</span>:163–4.</span> [<a href="/pubmed/15236416" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15236416</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.chen.2010.375">Chen CM, Lee LC, Soong BW, Fung HC, Hsu WC, Lin PY, Huang HJ, Chen FL, Lin CY, Lee-Chen GJ, Wu YR. SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications. <span><span class="ref-journal">Clin Chim Acta. </span>2010;<span class="ref-vol">411</span>:375–80.</span> [<a href="/pubmed/20004653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20004653</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.craig.2005.105">Craig K, Keers SM, Walls TJ, Curtis A, Chinnery PF. Minimum prevalence of spinocerebellar ataxia 17 in the north east of England. <span><span class="ref-journal">J Neurol Sci. </span>2005;<span class="ref-vol">239</span>:105–9.</span> [<a href="/pubmed/16223509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16223509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.doherty.2014.36">Doherty KM, Warner TT, Lees AJ. Late onset ataxia: MSA-C or SCA 17? A gene penetrance dilemma. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:36–8.</span> [<a href="/pubmed/24343983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24343983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.fujigasaki.2001.1939">Fujigasaki H, Martin JJ, De Deyn PP, Camuzat A, Deffond D, Stevanin G, Dermaut B, Van Broeckhoven C, Durr A, Brice A. CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. <span><span class="ref-journal">Brain. </span>2001;<span class="ref-vol">124</span>:1939–47.</span> [<a href="/pubmed/11571212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11571212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.gao.2008.215">Gao R, Matsuura T, Coolbaugh M, Z&#x000fc;lke C, Nakamura K, Rasmussen A, Siciliano MJ, Ashizawa T, Lin X. Instability of expanded CAG/CAA repeats in spinocerebellar ataxia type 17. <span><span class="ref-journal">Eur J Hum Genet. </span>2008;<span class="ref-vol">16</span>:215–22.</span> [<a href="/pubmed/18043721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18043721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.hagenah.2004.217">Hagenah JM, Z&#x000fc;hlke C, Hellenbroich Y, Heide W, Klein C. Focal dystonia as a presenting sign of spinocerebellar ataxia 17. <span><span class="ref-journal">Mov Disord. </span>2004;<span class="ref-vol">19</span>:217–20.</span> [<a href="/pubmed/14978680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14978680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.harbo.2009.777">Harbo HF, Finsterer J, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, De Jonghe P, Lossos A, Lynch T, Mariotti C, Sch&#x000f6;ls L, Spinazzola A, Szolnoki Z, Tabrizi SJ, Tallaksen C, Zeviani M, Burgunder JM, Gasser T. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. <span><span class="ref-journal">Eur J Neurol. </span>2009;<span class="ref-vol">16</span>:777–85.</span> [<a href="/pubmed/19469830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19469830</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.herrema.2014.269">Herrema H, Mikkelsen T, Robin A, LeWitt P, Sidiropoulos C. SCA 17 phenotype with intermediate triplet repeat number. <span><span class="ref-journal">J Neurol Sci. </span>2014;<span class="ref-vol">345</span>:269–70.</span> [<a href="/pubmed/25091452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25091452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.hire.2011.472">Hire RR, Katrak SM, Vadya S, Radhakrishnan K, Seshadri M. Spinocerebellar ataxia type 17 in Indian patients: two cases of homozygous expansions. <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">80</span>:472–7.</span> [<a href="/pubmed/21108634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21108634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.kim.2009.1385">Kim JY, Kim SY, Kim JM, Kim YK, Yoon KY, Kim JY. Spinocerebellar ataxia type 17 mutation as a causative and susceptibility gene in parkinsonism. <span><span class="ref-journal">Neurology. </span>2009;<span class="ref-vol">72</span>:1385–9.</span> [<a href="/pubmed/19380697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19380697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.koide.1999.2047">Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M, Yamada M, Takahashi H, Tsuji S. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:2047–53.</span> [<a href="/pubmed/10484774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10484774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.laplanche.1999.2375">Laplanche JL, Hachimi KH, Durieux I, Thuillet P, Defebvre L, Delasnerie-Laupr&#x000ea;tre N, Peoc'h K, Foncin JF, Dest&#x000e9;e A. Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. <span><span class="ref-journal">Brain. </span>1999;<span class="ref-vol">122</span>:2375–86.</span> [<a href="/pubmed/10581230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10581230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.lasek.2006.2341">Lasek K, Lencer R, Gaser C, Hagenah J, Walter U, Wolters A, Kock N, Steinlechner S, Nagel M, Z&#x000fc;hlke C, Nitschke MF, Brockmann K, Klein C, Rolfs A, Binkofski F. Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17). <span><span class="ref-journal">Brain. </span>2006;<span class="ref-vol">129</span>:2341–52.</span> [<a href="/pubmed/16760196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16760196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.maltecca.2003.1441">Maltecca F, Filla A, Castaldo I, Coppola G, Fragassi NA, Carella M, Bruni A, Cocozza S, Casari G, Servadio A, De Michele G. Intergenerational instability and marked anticipation in SCA-17. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">61</span>:1441–3.</span> [<a href="/pubmed/14638975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14638975</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.margolis.2001.373">Margolis RL, O'Hearn E, Rosenblatt A, Willour V, Holmes SE, Franz ML, Callahan C, Hwang HS, Troncoso JC, Ross CA. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">50</span>:373–80.</span> [<a href="/pubmed/11558794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11558794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.mariotti.2007.1538">Mariotti C, Alpini D, Fancellu R, Soliveri P, Grisoli M, Ravaglia S, Lovati C, Fetoni V, Giaccone G, Castucci A, Taroni F, Gellera C, Di Donato S. Spinocerebellar ataxia type 17 (SCA 17): oculomotor phenotype and clinical characterization of 15 Italian patients. <span><span class="ref-journal">J Neurol. </span>2007;<span class="ref-vol">254</span>:1538–46.</span> [<a href="/pubmed/17934876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17934876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.maruyama.2002.578">Maruyama H, Izumi Y, Morino H, Oda M, Toji H, Nakamura S, Kawakami H. Difference in disease-free survival curve and regional distribution according to subtype of spinocerebellar ataxia: a study of 1,286 Japanese patients. <span><span class="ref-journal">Am J Med Genet. </span>2002;<span class="ref-vol">114</span>:578–83.</span> [<a href="/pubmed/12116198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12116198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.moore.2001.1385">Moore RC, Xiang F, Monaghan J, Han D, Zhang Z, Edstr&#x000f6;m L, Anvret M, Prusiner SB. Huntington disease phenocopy is a familial prion disease. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:1385–8.</span> [<a href="/pmc/articles/PMC1235549/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235549</span></a>] [<a href="/pubmed/11593450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11593450</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.nakamura.2001.1441">Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:1441–8.</span> [<a href="/pubmed/11448935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11448935</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.nanda.2007.436">Nanda A, Jackson SA, Schwankhaus JD, Metzer WS. Case of spinocerebellar ataxia type 17 (SCA 17) associated with only 41 repeats of the TATA-binding protein (TBP) gene. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:436.</span> [<a href="/pubmed/17149738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17149738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.nielsen.2012.73">Nielsen TT, Mardosiene S, Lokkegaard A, Stokholm J, Ehrenfels S, Bech S, Friberg L, Nielsen JK, Nielsen JE. Severe and rapidly progressing cognitive phenotype in a SCA17-family with only marginally expanded CAG/CAA repeats in the TATA-box binding protein gene: a case report. <span><span class="ref-journal">BMC Neurol. </span>2012;<span class="ref-vol">12</span>:73–7.</span> [<a href="/pmc/articles/PMC3475097/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3475097</span></a>] [<a href="/pubmed/22889412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22889412</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.nolte.2010.1396">Nolte D, Sobanski E, Wissen A, Regula JU, Lichy C, M&#x000fc;ller U. Spinocerebellar ataxia type 17 associated with an expansion of 42 glutamine residues in TATA-box binding protein gene. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2010;<span class="ref-vol">81</span>:1396–9.</span> [<a href="/pubmed/20587494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20587494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.oda.2004.209">Oda M, Maruyama H, Komure O, Morino H, Terasawa H, Izumi Y, Imamura T, Yasuda M, Ichikawa K, Ogawa M, Matsumoto M, Kawakami H. Possible reduced penetrance of expansion of 44 to 47 CAG/CAA repeats in the TATA-binding protein gene in spinocerebellar ataxia type 17. <span><span class="ref-journal">Arch Neurol. </span>2004;<span class="ref-vol">61</span>:209–12.</span> [<a href="/pubmed/14967767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14967767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.park.2016.106">Park H, Jeon BS, Shin JH, Park SH. A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2016;<span class="ref-vol">22</span>:106–7.</span> [<a href="/pubmed/26613966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26613966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.rolfs.2003.367">Rolfs A, Koeppen AH, Bauer I, Bauer P, Buhlmann S, Topka H, Schols L, Riess O. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). <span><span class="ref-journal">Ann Neurol. </span>2003;<span class="ref-vol">54</span>:367–75.</span> [<a href="/pubmed/12953269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12953269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.shatunov.2004.496">Shatunov A, Fridman EA, Pagan FI, Leib J, Singleton A, Hallett M, Goldfarb LG. Small de novo duplication in the repeat region of the TATA-box-binding protein gene manifest with a phenotype similar to variant Creutzfeldt-Jakob disease. <span><span class="ref-journal">Clin Genet. </span>2004;<span class="ref-vol">66</span>:496–501.</span> [<a href="/pubmed/15521976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15521976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.silveira.2002.623">Silveira I, Miranda C, Guimaraes L, Moreira MC, Alonso I, Mendonca P, Ferro A, Pinto-Basto J, Coelho J, Ferreirinha F, Poirier J, Parreira E, Vale J, Januario C, Barbot C, Tuna A, Barros J, Koide R, Tsuji S, Holmes SE, Margolis RL, Jardim L, Pandolfo M, Coutinho P, Sequeiros J. Trinucleotide repeats in 202 families with ataxia: a small expanded (CAG)n allele at the SCA17 locus. <span><span class="ref-journal">Arch Neurol. </span>2002;<span class="ref-vol">59</span>:623–9.</span> [<a href="/pubmed/11939898" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11939898</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.stevanin.2008.170">Stevanin G, Brice A. Spinocerebellar ataxia 17 (SCA 17) and Huntington&#x02019;s disease-like 4 (HDL4). <span><span class="ref-journal">Cerebellum. </span>2008;<span class="ref-vol">7</span>:170–8.</span> [<a href="/pubmed/18418687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18418687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.stevanin.2003.1599">Stevanin G, Fujigasaki H, Lebre AS, Camuzat A, Jeannequin C, Dode C, Takahashi J, San C, Bellance R, Brice A, Durr A. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. <span><span class="ref-journal">Brain. </span>2003;<span class="ref-vol">126</span>:1599–603.</span> [<a href="/pubmed/12805114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12805114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.schneider.2007.517">Schneider SA, Walker RH, Bhatia K. The Huntington&#x02019;s disease-like syndromes: what to consider in patients with a negative Huntington&#x02019;s disease gene test. <span><span class="ref-journal">Nat Clin Pract Neurol. </span>2007;<span class="ref-vol">3</span>:517–25.</span> [<a href="/pubmed/17805246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17805246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.toyoshima.2018.219">Toyoshima Y, Takahashi H. Spinocerebellar ataxia type 17 (SCA17). <span><span class="ref-journal">Adv Exp Med Biol. </span>2018;<span class="ref-vol">1049</span>:219–31.</span> [<a href="/pubmed/29427105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29427105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.toyoshima.2004.281">Toyoshima Y, Yamada M, Onodera O, Shimohata M, Inenaga C, Fujita N, Morita M, Tsuji S, Takahashi H. SCA 17 homozygote showing Huntington's disease-like phenotype. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:281–6.</span> [<a href="/pubmed/14755733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14755733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.wu.2005.539">Wu YR, Fung HC, Lee-Chen GJ, Gwinn-Hardy K, Ro LS, Chen ST, Hsieh-Li HM, Lin HY, Lin CY, Li SN, Chen CM. Analysis of polyglutamine-coding repeats in the TATA-binding protein in different neurodegenerative diseases. <span><span class="ref-journal">J Neural Transm. </span>2005;<span class="ref-vol">112</span>:539–46.</span> [<a href="/pubmed/15365789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15365789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.xiang.1998.1431">Xiang F, Almqvist EW, Huq M, Lundin A, Hayden MR, Edstrom L, Anvret M, Zhang Z. A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">63</span>:1431–8.</span> [<a href="/pmc/articles/PMC1377554/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377554</span></a>] [<a href="/pubmed/9792871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9792871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.z_hlke.2005.27">Z&#x000fc;hlke C, Dalski A, Schwinger E, Finckh U. Spinocerebellar ataxia type 17: report of a family with reduced penetrance of an unstable Gln49 TBP allele, haplotype analysis supporting a founder effect for unstable alleles and comparative analysis of SCA17 genotypes. <span><span class="ref-journal">BMC Med Genet. </span>2005;<span class="ref-vol">6</span>:27.</span> [<a href="/pmc/articles/PMC1177950/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1177950</span></a>] [<a href="/pubmed/15989694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15989694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.z_hlke.2003a.161">Z&#x000fc;hlke C, Gehlken U, Hellenbroich Y, Schwinger E, B&#x000fc;rk K. Phenotypical variability of expanded alleles in the TATA-binding protein gene. Reduced penetrance in SCA17? <span><span class="ref-journal">J Neurol. </span>2003a;<span class="ref-vol">250</span>:161–3.</span> [<a href="/pubmed/12574945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12574945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.z_hlke.2001.160">Z&#x000fc;hlke C, Hellenbroich Y, Dalski A, Kononowa N, Hagenah J, Vieregge P, Riess O, Klein C, Schwinger E. Different types of repeat expansion in the TATA-binding protein gene are associated with a new form of inherited ataxia. <span><span class="ref-journal">Eur J Hum Genet. </span>2001;<span class="ref-vol">9</span>:160–4.</span> [<a href="/pubmed/11313753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11313753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sca17.REF.z_hlke.2003b.629">Z&#x000fc;hlke CH, Spranger M, Spranger S, Voigt R, Lanz M, Gehlken U, Hinrichs F, Schwinger E. SCA17 caused by homozygous repeat expansion in TBP due to partial isodisomy 6. <span><span class="ref-journal">Eur J Hum Genet. </span>2003b;<span class="ref-vol">11</span>:629–32.</span> [<a href="/pubmed/12891385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12891385</span></a>]</div></li></ul></div></div><div id="sca17.Chapter_Notes"><h2 id="_sca17_Chapter_Notes_">Chapter Notes</h2><div id="sca17.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 September 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 May 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 August 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>29 March 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>24 August 2004 (yt) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1438</span><span class="label">PMID: <a href="/pubmed/20301611" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301611</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sca15/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sca20/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1438&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1438/?report=reader">PubReader</a></li><li><a href="/books/NBK1438/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1438" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1438" style="display:none" title="Cite this Page"><div class="bk_tt">Toyoshima Y, Onodera O, Yamada M, et al. Spinocerebellar Ataxia Type 17. 2005 Mar 29 [Updated 2019 Sep 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1438/pdf/Bookshelf_NBK1438.pdf">PDF version of this page</a> (509K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#sca17.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#sca17.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#sca17.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#sca17.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#sca17.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#sca17.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#sca17.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#sca17.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#sca17.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#sca17.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#sca17.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6908[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TBP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1467126" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1467126" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1467126" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1467126" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14967767" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Possible reduced penetrance of expansion of 44 to 47 CAG/CAA repeats in the TATA-binding protein gene in spinocerebellar ataxia type 17.</a><span class="source">[Arch Neurol. 2004]</span><div class="brieflinkpop offscreen_noflow">Possible reduced penetrance of expansion of 44 to 47 CAG/CAA repeats in the TATA-binding protein gene in spinocerebellar ataxia type 17.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Oda M, Maruyama H, Komure O, Morino H, Terasawa H, Izumi Y, Imamura T, Yasuda M, Ichikawa K, Ogawa M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Neurol. 2004 Feb; 61(2):209-12. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17853080" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar ataxia type 17 is caused by mutations in the TATA-box binding protein.</a><span class="source">[Cerebellum. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar ataxia type 17 is caused by mutations in the TATA-box binding protein.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zühlke C, Bürk K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cerebellum. 2007; 6(4):300-7. Epub 2007 Jan 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15989694" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Spinocerebellar ataxia type 17: report of a family with reduced penetrance of an unstable Gln49 TBP allele, haplotype analysis supporting a founder effect for unstable alleles and comparative analysis of SCA17 genotypes.</a><span class="source">[BMC Med Genet. 2005]</span><div class="brieflinkpop offscreen_noflow">Spinocerebellar ataxia type 17: report of a family with reduced penetrance of an unstable Gln49 TBP allele, haplotype analysis supporting a founder effect for unstable alleles and comparative analysis of SCA17 genotypes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zühlke C, Dalski A, Schwinger E, Finckh U. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Med Genet. 2005 Jul 1; 6:27. Epub 2005 Jul 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29564144" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier.</a><span class="source">[Cerebellum Ataxias. 2018]</span><div class="brieflinkpop offscreen_noflow">Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origone P, Gotta F, Lamp M, Trevisan L, Geroldi A, Massucco D, Grazzini M, Massa F, Ticconi F, Bauckneht M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cerebellum Ataxias. 2018; 5:7. Epub 2018 Mar 14.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29427105" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 17 (SCA17).</a><span class="source">[Adv Exp Med Biol. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 17 (SCA17).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Toyoshima Y, Takahashi H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Adv Exp Med Biol. 2018; 1049:219-231. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301611" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301611" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04189b39a66ee2ba434d98">Spinocerebellar Ataxia Type 17 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Spinocerebellar Ataxia Type 17 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:19:08-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A2655E0414E6100000000019F009F&amp;ncbi_session=CE8A2655E04189B1_0415SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1438%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1438&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1438/&amp;ncbi_pagename=Spinocerebellar Ataxia Type 17 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A2655E04189B1_0415SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>